Volume 23, Number 3—March 2017
Dispatch
Likely Autochthonous Transmission of Trypanosoma cruzi to Humans, South Central Texas, USA
Table 1
Donor no./age, y/sex |
Likely autochthonous transmission† |
Blood bank serologic test results‡ |
Study serologic test results§ |
ECG results¶ |
Concurent condition |
||||||
PRISM or ORTHO |
RIPA or ESA |
Hemagen |
Stat-Pak |
DPP |
EIA |
TESA |
|||||
1/83/M | Yes | + | + | + | + | + | + | + | Primary AV block, atypical incomplete right BBB, lateral asymmetric T inversion | None | |
2/61/F | Yes | + | + | + | + | + | + | + | Inferolateral asymmetric T inversion | Hypertension | |
3/71/M | Yes | + | + | + | + | + | + | + | LAD, nonspecific ST/T wave abnormality | Kidney failure, hypertension | |
5/19/M | Yes | + | + | + | + | + | + | + | Normal | None | |
6/60/M | Yes | + | + | + | + | + | + | + | Primary AV block | Diabetes, hypertension | |
7/56/F | Yes | + | + | + | + | + | – | + | Minimum voltage criteria for LVH | None | |
8/52/M | Yes | + | + | + | + | + | + | + | LAD | Parkinson’s disease | |
9/25/F | Yes | + | + | + | + | + | + | + | Normal | None | |
10/51/F | Yes | + | + | + | + | + | Ind | + | Normal | Heart attack | |
11/52/F | Yes | + | + | + | + | + | + | + | Normal | None | |
12/45/M | No | + | + | + | + | + | + | + | Normal | Borderline diabetes | |
13/35/F | No | + | + | + | + | + | + | + | Normal | None | |
14/34/F | No | + | + | Ind | + | + | + | + | Nonspecific T wave change | None |
*Demographic information, likely autochthonous transmission, and concurrent conditions were determined through case-patient interview. ECG, electrocardiogam; Ind, indeterminate; +, positive; –, negative. Test results were based on manufacturers’ protocols for serologic testing.
†Donors listed as showing autochthonous transmission (donors 12–14) reported living in Mexico or Chile.
‡ESA, Chagas Test (Abbott Laboratories, Chicago, IL, USA); ORTHO, T. cruzi ELISA (Ortho-Clinical Diagnostics Inc., Raritan, NJ, USA); PRISM, Chemiluminescent Immunoassay (Abbott Laboratories); RIPA, radioimmune precipitation assay (Quest Diagnostic Laboratories, Madison, NJ, USA).
§DPP, dual path platform immunochromatographic confirmation assay (Chembio, Medford, NY, USA); EIA, Chagatest recombinant v3.0 enzyme inmmunoassay (Wiener, Rosario, Argentina); Hemagen; Chagas EIA Kit (Hemagen Diagnostics, Inc., Columbia, MD, USA); Stat-Pak, Chagas immunochromatographic sssay (Chembio, Medford, NY, USA); TESA, trypomastigote excreted or secreted antigen immunoblot (bioMérieux, Marcy l’Etoile, France). Hemagen, Stat-Pak, and DPP were performed at Baylor College of Medicine, (Houston, TX, USA), and EIA and TESA were performed at the Centers for Disease Control and Prevention (Atlanta, GA, USA).
¶Results were determined from readout of a resting 12-lead ECG and interpreted by a board-certified cardiologist. AV, atrioventricular; LAD, left axis deviation; LVH, left ventricular hypertrophy; RBBB, right bundle branch block.